{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:35:37Z","timestamp":1793594137649,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":927,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ijid.2010.03.025","type":"journal-article","created":{"date-parts":[[2010,11,12]],"date-time":"2010-11-12T07:19:52Z","timestamp":1289546392000},"page":"e2-e16","source":"Crossref","is-referenced-by-count":195,"title":["Does rituximab increase the incidence of infectious complications? A narrative review"],"prefix":"10.1016","volume":"15","author":[{"given":"Theodoros","family":"Kelesidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2010.03.025_bib0005","unstructured":"US Food and Drug Administration. FDA alert: rituximab (marketed as Rituxan). Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm109106.htm (accessed August 1, 2009)."},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2010.03.025_bib0010","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3816\/CLM.2006.s.002","article-title":"Treatment of non-Hodgkin's lymphoma: a look over the past decade","volume":"7","author":"Coiffier","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0015","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","article-title":"Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up","volume":"22","author":"Czuczman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0020","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1517\/14656566.7.18.2559","article-title":"Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis","volume":"7","author":"Dass","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijid.2010.03.025_bib0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","article-title":"Rituximab-related viral infections in lymphoma patients","volume":"48","author":"Aksoy","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0030","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection","volume":"176","author":"Lund","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/vir.0.18678-0","article-title":"Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent","volume":"84","author":"Lazdina","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/152581603321210082","article-title":"Long-lasting hypogammaglobulinemia following rituximab administration for Epstein\u2013Barr virus-related post-transplant lymphoproliferative disease preemptive therapy","volume":"12","author":"Castagnola","year":"2003","journal-title":"J Hematother Stem Cell Res"},{"key":"10.1016\/j.ijid.2010.03.025_bib0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10428190701742506","article-title":"B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period","volume":"49","author":"Lim","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-642-56352-2_18","article-title":"Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I\/II study","volume":"159","author":"Tirelli","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ijid.2010.03.025_bib0075","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijid.2010.03.025_bib0080","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-200201150-00019","article-title":"Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication","volume":"73","author":"Verschuuren","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ijid.2010.03.025_bib0085","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1012500524758","article-title":"Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG","volume":"12","author":"Saikia","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00277-003-0758-2","article-title":"Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma","volume":"83","author":"Yokohama","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-007-0397-0","article-title":"Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation","volume":"87","author":"Lee","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00277-006-0191-4","article-title":"Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP","volume":"86","author":"Lin","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0105","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3748\/wjg.v12.i12.1978","article-title":"Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin's lymphoma patient","volume":"12","author":"Unluturk","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0110","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0115","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10428190902730219","article-title":"Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis","volume":"50","author":"Aksoy","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 3","key":"10.1016\/j.ijid.2010.03.025_bib0120","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2007.081430","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ijid.2010.03.025_bib0125","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2008.100834","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008","volume":"67","author":"Furst","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0130","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","article-title":"Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials","volume":"109","author":"Rafailidis","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijid.2010.03.025_bib0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0140","doi-asserted-by":"crossref","unstructured":"Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2009 (2) CD006552.","DOI":"10.1002\/14651858.CD006552.pub2"},{"key":"10.1016\/j.ijid.2010.03.025_bib0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0150","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0155","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0160","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0165","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0175","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0180","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0185","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0190","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0200","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3324\/haematol.11903","article-title":"High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy","volume":"93","author":"Dungarwalla","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ijid.2010.03.025_bib0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijid.2010.03.025_bib0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12185-008-0066-7","article-title":"Increased incidence of interstitial pneumonia by CHOP combined with rituximab","volume":"87","author":"Ennishi","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0215","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0220","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0225","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0230","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0235","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.1999.01364.x","article-title":"Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study","volume":"105","author":"Byrd","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","article-title":"Risk factors for infection in haematology patients treated with rituximab","volume":"82","author":"Kanbayashi","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0250","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/ard.2008.101675","article-title":"Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients","volume":"68","author":"Genovese","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0255","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0260","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0265","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0270","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0275","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","article-title":"The risk of infections with biologic therapies for rheumatoid arthritis","volume":"39","author":"Furst","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.ijid.2010.03.025_bib0285","first-page":"558","article-title":"Safety of rituximab therapy for prevention or treatment of acute humoral rejection after renal transplantation","volume":"9","author":"Scemla","year":"2008","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.ijid.2010.03.025_bib0290","first-page":"564","article-title":"Risk of infection in kidney-transplant recipients treated with rituximab","volume":"9","author":"Tsapepas","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0295","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-0012.2007.00700.x","article-title":"Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients","volume":"21","author":"Grim","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0300","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1432-2277.2009.00903.x","article-title":"Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy","volume":"22","author":"Nishida","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijid.2010.03.025_bib0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","article-title":"Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients","volume":"24","author":"Lovric","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0315","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1432-2277.2009.00896.x","article-title":"Treatment of symptomatic transplant glomerulopathy with rituximab","volume":"22","author":"Rostaing","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijid.2010.03.025_bib0320","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with rituximab: a GITMO study","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0325","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705766","article-title":"Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment","volume":"40","author":"Arber","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0330","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3201\/eid1411.080003","article-title":"Bacteremia caused by Mycobacterium wolinskyi","volume":"14","author":"Chen","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0335","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","author":"Lutt","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0340","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJM200109273451315","article-title":"Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder","volume":"345","author":"Suzan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0345","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03006938","article-title":"Prolonged reactivation of cytomegalovirus infection following successful rituximab therapy for Epstein\u2013Barr virus-associated posttransplantation lymphoproliferative disorder","volume":"86","author":"Hirokawa","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0350","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.transproceed.2004.06.044","article-title":"Heart transplant coronary artery disease in Chinese recipients","volume":"36","author":"Lee","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijid.2010.03.025_bib0355","first-page":"119","article-title":"Cytomegalovirus infection of endocrine system in a patient with diffuse large B-cell lymphoma","volume":"95","author":"Stathis","year":"2009","journal-title":"Report of a case. Tumori"},{"key":"10.1016\/j.ijid.2010.03.025_bib0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/cbr.2008.0507","article-title":"Rituximab and chemotherapy in primary gastric lymphoma","volume":"24","author":"Aviles","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijid.2010.03.025_bib0365","first-page":"894","article-title":"Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma","volume":"85","author":"Bermudez","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.ijid.2010.03.025_bib0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2257.2001.00397.x","article-title":"Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post rituximab and autologous stem cell transplantation","volume":"23","author":"McIlwaine","year":"2001","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0375","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2005-873014","article-title":"Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma","volume":"114","author":"Scheinpflug","year":"2006","journal-title":"A case report. Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ijid.2010.03.025_bib0380","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/07357900600815232","article-title":"B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis","volume":"24","author":"Coiffier","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijid.2010.03.025_bib0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00277-007-0396-1","article-title":"Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma","volume":"87","author":"Yang","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0390","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2010.03.025_bib0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-150-6-200903170-00026","article-title":"Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab","volume":"150","author":"Ollier","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0400","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0405","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002770100346","article-title":"Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report","volume":"80","author":"Ng","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0410","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0415","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ajh.21214","article-title":"Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?","volume":"83","author":"Garcia-Rodriguez","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0420","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10156-005-0385-Z","article-title":"HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb","volume":"11","author":"Sarrecchia","year":"2005","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2010.03.025_bib0425","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2403914","article-title":"Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy","volume":"19","author":"Niscola","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ijid.2010.03.025_bib0430","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2169\/internalmedicine.45.1590","article-title":"Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab","volume":"45","author":"Sera","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0435","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0440","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","article-title":"Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy","volume":"102","author":"Westhoff","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0445","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/10428190601059704","article-title":"Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab","volume":"48","author":"Yamagata","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0450","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1042819031000151923","article-title":"Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy","volume":"45","author":"Tsutsumi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0455","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2133.2006.07451.x","article-title":"Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma","volume":"155","author":"Perceau","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0460","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12072-008-9094-x","article-title":"A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma","volume":"3","author":"Takahashi","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijid.2010.03.025_bib0465","first-page":"201","article-title":"Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection","volume":"15","author":"Mak","year":"2009","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.ijid.2010.03.025_bib0470","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-150-9-200905050-00024","article-title":"virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma","volume":"150","author":"Koo","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2010.03.025_bib0475","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0480","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0485","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.20200","article-title":"Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy","volume":"77","author":"Isobe","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0490","doi-asserted-by":"crossref","DOI":"10.1086\/345746","article-title":"Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment","volume":"36","author":"Quartier","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0495","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2257.2006.00751.x","article-title":"Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab","volume":"28","author":"Padate","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0500","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2141.2009.07748.x","article-title":"Enterovirus infection of neuronal cells post-rituximab","volume":"146","author":"Kiani-Alikhan","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0505","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.V99.4.1486","article-title":"Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab","volume":"99","author":"Goldberg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0510","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/rheumatology\/kem299","article-title":"Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab.","volume":"47","author":"Harris","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijid.2010.03.025_bib0515","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5414\/NPP26068","article-title":"Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature","volume":"26","author":"Freim Wahl","year":"2007","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0520","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0525","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2008.01101.x","article-title":"BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab","volume":"81","author":"Ferrari","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0530","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2002-04-1271","article-title":"Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody","volume":"100","author":"Matteucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0535","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.20540","article-title":"Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma","volume":"81","author":"Ozgonenel","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0540","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijid.2010.03.025_bib0545","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3816\/CLM.2005.n.053","article-title":"Fatal West Nile virus infection after rituximab\/fludarabine\u2014induced remission for non-Hodgkin's lymphoma","volume":"6","author":"Mawhorter","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ijid.2010.03.025_bib0550","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3201\/eid0812.020532","article-title":"First isolation of West Nile virus from a patient with encephalitis in the United States","volume":"8","author":"Huang","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0555","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1399-0012.2009.01044.x","article-title":"Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients","volume":"24","author":"Levi","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0560","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0565","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1726-4901(08)70173-4","article-title":"Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab","volume":"71","author":"Chang","year":"2008","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.ijid.2010.03.025_bib0570","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ijid.2010.03.025_bib0575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen","volume":"92","author":"Kolstad","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ijid.2010.03.025_bib0580","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome: a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ijid.2010.03.025_bib0585","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00277-006-0206-1","article-title":"Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura","volume":"86","author":"Fianchi","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0590","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-006-0129-x","article-title":"Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder","volume":"85","author":"van der Velden","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0595","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0037-1617028","article-title":"Inhibitor treatment by rituximab in congenital haemophilia A\u2014two case reports","volume":"29","author":"Streif","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ijid.2010.03.025_bib0600","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00277-003-0748-4","article-title":"Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma","volume":"83","author":"Tsutsumi","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0605","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0610","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","article-title":"Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier","volume":"20","author":"Fukushima","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.ijid.2010.03.025_bib0615","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1200\/jco.2005.23.16_suppl.2562","article-title":"Opportunistic infections (OI) following monoclonal antibody treatment Proceedings of the ASCO Annual Meeting 2005","volume":"23","author":"Cornely","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0620","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2407-8-115","article-title":"Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijid.2010.03.025_bib0625","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ijid.2010.03.025_bib0630","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00431-009-1000-6","article-title":"Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier","volume":"169","author":"Aomatsu","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ijid.2010.03.025_bib0635","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2257.2006.00779.x","article-title":"Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient","volume":"28","author":"Aksoy","year":"2006","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0640","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/039139880703000513","article-title":"Hepatitis C virus infection and rituximab therapy after renal transplantation","volume":"30","author":"Fabrizi","year":"2007","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.ijid.2010.03.025_bib0645","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0650","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/039139880903200508","article-title":"Application of rituximab to hepatitis C-positive ABO-incompatible renal transplantation","volume":"32","author":"Tsai","year":"2009","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.ijid.2010.03.025_bib0655","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","article-title":"Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy","volume":"17","author":"Visco","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0660","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.V106.11.2447.2447","article-title":"Diffuse B-large cell lymphomas (DBLCL) with hepatitis-C virus (HCV) infection: clinical outcome and preliminary results of a pilot study combining R-CHOP with antiviral therapy","volume":"106","author":"Musto","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0665","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0670","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijid.2010.03.025_bib0675","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/589714","article-title":"Oropharyngeal shedding of Epstein\u2013Barr virus in the absence of circulating B cells","volume":"198","author":"Hoover","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2010.03.025_bib0680","unstructured":"Medicines and Healthcare Products Regulatory Agency (UK). Information sent to healthcare professionals in November 2008 about the safety of medicines. Available at: http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines\/CON031203 (accessed August 30, 2009)."},{"key":"10.1016\/j.ijid.2010.03.025_bib0685","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0690","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2010.03.025_bib0695","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/eji.200323790","article-title":"A role for antibodies in the generation of memory antifungal immunity","volume":"33","author":"Montagnoli","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0700","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijid.2010.03.025_bib0705","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.23171","article-title":"The effects of rituximab on immunocompetency in patients with autoimmune disease","volume":"58","author":"Looney","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0710","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ijid.2010.03.025_bib0715","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121002504X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121002504X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T15:15:26Z","timestamp":1740669326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121002504X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S120197121002504X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2010.03.025","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}